Amarin (AMRN) vs Lyell Immunopharma (LYEL)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Lyell Immunopharma (LYEL) has outperformed Amarin (AMRN) over the past year, losing 27.9% versus a loss of 35.5%. Over five years, AMRN leads with a -85.5% price change compared with -92.6% for LYEL. Amarin is the larger company by market cap ($444.4 million vs $441.8 million), about 1.0 times the size.
Amarin converts more of its revenue into profit, with a net margin of -18.2% versus -762355.6%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AMRN | LYEL |
|---|---|---|
| Share price | $10.57 | $13.80 |
| Market cap | $444.39M | $441.82M |
| 1-day change | -6.13% | +1.62% |
| YTD return | -24.28% | -55.17% |
| 1-year return | -35.47% | -27.86% |
| 5-year return | -85.48% | -92.59% |
| Forward P/E | 10.79 | — |
| EPS (TTM) | $-0.80 | $-12.61 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $213.65M | $36.00K |
| Revenue growth (YoY) | -6.55% | -40.98% |
| Net income (latest FY) | $-38.80M | $-274.45M |
| Gross margin | 56.57% | — |
| Operating margin | -23.48% | -748344.44% |
| Net margin | -18.16% | -762355.56% |
| 52-week high | $17.31 | $45.00 |
| 52-week low | $10.56 | $7.20 |
| Distance from 52-week high | -38.94% | -69.33% |
| Analyst consensus | none | buy |
| Avg. price target upside | +22.99% | +172.68% |
| Average volume | 79.50K | 174.76K |
| Shares outstanding | 42.04M | 32.02M |
| Employees | 80 | 161 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Amarin is more profitable, keeping -18.2 cents of every revenue dollar as net income versus -762355.6 cents for Lyell Immunopharma.
- Amarin grew revenue faster in its latest fiscal year (-6.55% vs -40.98%).
About Amarin
AMRN stock →Amarin Corporation plc, a pharmaceutical company, engages in the commercialization and development of therapeutics for the treatment of cardiovascular diseases in the United States, Europe, and internationally. It offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia.
Health Care · Biotechnology: Pharmaceutical Preparations · 80 employees
About Lyell Immunopharma
LYEL stock →Lyell Immunopharma, Inc., a clinical-stage cell therapy company, develops chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The company's lead product candidate include rondecabtagene autoleucel, an autologous dual-targeting CD19/CD20 CAR T-cell therapy in development, which is in pivotal PiNACLE trial in the 3L+ setting and in a Phase 1/2 clinical trial in the 2L setting, as well as a second pivotal trial, PiNACLE-H2H, which is a Phase 3 head-to-head CAR T cell therapy randomized controlled trial of ronde-cel for LBCL in the 2L setting for the treatment of large B-cell lymphoma; and LYL273, a GCC-targeted CAR T-cell product candidate enhanced with CD19 CAR expression and controlled cytokine release designed to improve CAR T-cell expansion, immune cell infiltration, and cancer cell killing in the hostile solid tumor microenvironment, which is in Phase 1 clinical trial for the treatment of refractory metastatic colorectal cancer.
Health Care · Biotechnology: Pharmaceutical Preparations · 161 employees
AMRN vs LYEL FAQ
Which is bigger, Amarin or Lyell Immunopharma?
Amarin (AMRN) is larger, with a market capitalization of $444.39M compared with $441.82M for Lyell Immunopharma (LYEL).
Which stock has performed better over the past year, AMRN or LYEL?
LYEL returned -27.86% over the past 12 months, compared with -35.47% for AMRN (price return, excluding dividends). Past performance does not predict future results.
Are Amarin and Lyell Immunopharma in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.